SynthesisBMC immunology2026
Causal associations between Sjögren's syndrome and subtypes of endometrial cancer.
Synthesis in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEndometrial cancer (EC) is a heterogeneous gynecologic malignancy with distinct histological subtypes and diverse etiological factors. While autoimmune diseases have been associated with cancer development, the causal relationship between Sjögren’s syndrome (SS) and EC remains unclear. In this study, we employed a Mendelian randomization (MR) approach to investigate this complex association.
methodsWe conducted a two-sample MR study using genome-wide association study summary statistics from European ancestry cohorts. Genetic instruments for SS were derived from the FinnGen consortium, and outcome data for EC, including its endometrioid and non-endometrioid subtypes, were obtained from a large-scale EC meta-analysis. Multiple MR methods and sensitivity analyses were applied to assess robustness and detect pleiotropy.
resultsGenetically predicted SS was causally associated with an increased risk of overall EC (OR = 1.1480, 95% CI: 1.0511–1.2537, P = 0.0155), particularly endometrioid EC (OR = 1.1603, 95% CI: 1.0442–1.2894, P = 0.0207). No causal association was observed with non-endometrioid EC (OR = 1.0844, 95% CI: 0.8018–1.4665, P = 0.4560). Sensitivity analyses revealed no significant heterogeneity or horizontal pleiotropy, supporting the robustness of the findings.
conclusionsThis MR study provides genetic evidence for a causal relationship between SS and increased risk of endometrioid EC, but not non-endometrioid EC. These findings suggest subtype-specific immune mechanisms underlying EC development and may inform targeted screening strategies for women with SS. Future research should explore the immuno-hormonal pathways linking autoimmunity and endometrial carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.